Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis

Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis

In 215 patients with a median age of 16 years, fingolimod was superior to interferon beta-1a in reducing relapses of multiple sclerosis and the accumulation of new lesions on MRI over a 2-year period. Seizures occurred in 5.6% of patients in the fingolimod group.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2018-09, Vol.379 (11), p.1017-1027
Hauptverfasser: Chitnis, Tanuja, Arnold, Douglas L, Banwell, Brenda, Brück, Wolfgang, Ghezzi, Angelo, Giovannoni, Gavin, Greenberg, Benjamin, Krupp, Lauren, Rostásy, Kevin, Tardieu, Marc, Waubant, Emmanuelle, Wolinsky, Jerry S, Bar-Or, Amit, Stites, Tracy, Chen, Yu, Putzki, Norman, Merschhemke, Martin, Gärtner, Jutta
Format: Artikel
Sprache:eng
Schlagworte:
Administration, Oral
Adolescent
Adults
Age
Body weight
Brain - diagnostic imaging
Brain - pathology
Child
Clinical trials
Convulsions
FDA approval
Female
Fingolimod Hydrochloride - adverse effects
Fingolimod Hydrochloride - therapeutic use
Headache - chemically induced
Humans
Immunologic Factors - adverse effects
Immunologic Factors - therapeutic use
Infection - chemically induced
Injections, Intramuscular
Interferon
Interferon-beta - adverse effects
Interferon-beta - therapeutic use
Leukopenia
Leukopenia - chemically induced
Life Sciences
Magnetic Resonance Imaging
Male
Multiple sclerosis
Multiple Sclerosis, Relapsing-Remitting - drug therapy
NMR
Nuclear magnetic resonance
Patients
Pediatrics
Regulatory approval
Secondary Prevention
Tachycardia
Technical communication
β-Interferon
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In 215 patients with a median age of 16 years, fingolimod was superior to interferon beta-1a in reducing relapses of multiple sclerosis and the accumulation of new lesions on MRI over a 2-year period. Seizures occurred in 5.6% of patients in the fingolimod group.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa1800149